CD38 and acute myeloid leukemia: The newly diagnosed AML patients showed a significantly elevated TIM-3+ frequency in the CD34+CD38− population compared to HDs (median (range): 7.8% (0.21–53.2%) vs. 0.74% (0–3.8%), p < 0.001, Figure 1A).